Legal & General Group Plc acquired a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,228 shares of the biopharmaceutical company’s stock, valued at approximately $212,000. Legal & General Group Plc owned 0.06% of Assembly Biosciences as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of Assembly Biosciences by 11.2% during the 1st quarter. Vanguard Group Inc. now owns 503,851 shares of the biopharmaceutical company’s stock worth $12,843,000 after purchasing an additional 50,615 shares during the period. Lyon Street Capital LLC acquired a new position in shares of Assembly Biosciences during the 1st quarter worth $767,000. Geode Capital Management LLC grew its stake in shares of Assembly Biosciences by 32.3% during the 1st quarter. Geode Capital Management LLC now owns 97,964 shares of the biopharmaceutical company’s stock worth $2,497,000 after purchasing an additional 23,926 shares during the period. Victory Capital Management Inc. acquired a new position in shares of Assembly Biosciences during the 1st quarter worth $580,000. Finally, Arthur M. Cohen & Associates LLC acquired a new position in shares of Assembly Biosciences during the 2nd quarter worth $403,000. 72.27% of the stock is currently owned by institutional investors.

ASMB has been the topic of a number of recent analyst reports. BidaskClub raised shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 3rd. Zacks Investment Research cut shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th.

Assembly Biosciences, Inc. (NASDAQ ASMB) opened at 34.34 on Friday. Assembly Biosciences, Inc. has a 1-year low of $10.93 and a 1-year high of $36.31. The stock’s 50 day moving average is $30.95 and its 200-day moving average is $25.21. The firm’s market capitalization is $596.28 million.

COPYRIGHT VIOLATION NOTICE: “10,228 Shares in Assembly Biosciences, Inc. (ASMB) Acquired by Legal & General Group Plc” was first published by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/10/13/10228-shares-in-assembly-biosciences-inc-asmb-acquired-by-legal-general-group-plc.html.

Assembly Biosciences Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Want to see what other hedge funds are holding ASMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assembly Biosciences, Inc. (NASDAQ:ASMB).

Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.